Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13362.5 | 90 | |
| RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13556.0 | 73 | |
| RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 1686.0 | 64 | |
| RA2159 | PI103 | 0.1 | uM | 3 | MCP-1 (MCAF) | 3807.0 | 59 | ||||
| N2586 | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12984.5 | 88 | ||||
| N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12458.5 | 74 | |
| N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13232.0 | 67 | |
| N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12575.0 | 75 | |
| N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 10789.0 | 79 | |
| N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12302.0 | 69 | |
| N2586 | PI103 | 0.1 | uM | 3 | MCP-1 (MCAF) | 4110.0 | 87 | ||||
| 0 | MCP-1 (MCAF) | 60.0 | 65 | ||||||||
| RA2159 | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12144.0 | 54 | ||||
| RA2159 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 11738.5 | 50 | |
| RA2159 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13016.0 | 55 | |
| RA2159 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13130.0 | 97 | |
| RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12866.5 | 74 | |
| RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 5409.0 | 53 | |
| RA2159 | EO1428 | 1.0 | uM | 3 | MCP-1 (MCAF) | 3958.0 | 63 | ||||
| N2586 | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 12016.0 | 81 | ||||
| N2586 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13439.0 | 74 | |
| N2586 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 13646.0 | 65 | |
| N2586 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 10623.0 | 78 | |
| N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 11318.0 | 68 | |
| N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MCP-1 (MCAF) | 11726.0 | 78 |